HuGE Literature Finder
|
||
Records 1-15
|
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Human pathology 2018 Sep . Shaukat Irfan, Kern Jason J, Höti Naseruddin, Zhang H, Li Jason, Zheng Gang, Askin Frederic, Gabrielson Edward, Li Qing K |
|
Phosphorylation of p70 Ribosomal Protein S6 Kinase ?-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.
Clinical colorectal cancer 2018 Feb . Wiesweg Marcel, Reis Henning, Köster Tobias, Goetz Moritz, Worm Karl, Herold Thomas, Paul Andreas, Dechêne Alexander, Schumacher Brigitte, Markus Peter, Virchow Isabel, Kostbade Karina, Wolf Nathalie, Zaun Gregor, Metzenmacher Martin, Schmid Kurt W, Schuler Martin, Kasper Stef |
|
Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
Journal of thoracic disease 2018 Jan 10 (1): 398-407. Zhao Mengnan, Zhan Cheng, Li Ming, Yang Xiaodong, Yang Xinyu, Zhang Yong, Lin Miao, Xia Yifeng, Feng Mingxiang, Wang Q |
|
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Cancer 2017 May . Lee Dae-Won, Han Sae-Won, Cha Yongjun, Bae Jeong Mo, Kim Hwang-Phill, Lyu Jaemyun, Han Hyojun, Kim Hyoki, Jang Hoon, Bang Duhee, Huh Iksoo, Park Taesung, Won Jae-Kyung, Jeong Seung-Yong, Park Kyu Joo, Kang Gyeong Hoon, Kim Tae-Y |
|
Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.
Wiener klinische Wochenschrift 2017 May . Rendl Gundula, Rodrigues Margarida, Schweighofer-Zwink Gregor, Hutter Josef, Hittmair Anton, Zellinger Barbara, Hauser-Kronberger Cornelia, Pirich Christi |
|
Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis.
Molecular and clinical oncology 2017 Mar 6 (3): 403-408. Garde Noguera Javier, Jantus-Lewintre Eloisa, Gil-Raga Mireia, Evgenyeva Elena, Maciá Escalante Sonia, Llombart-Cussac Antonio, Camps Herrero Carl |
|
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Cancer 2015 Feb 121 (3): 448-56. Villaruz Liza C, Socinski Mark A, Abberbock Shira, Berry Lynne D, Johnson Bruce E, Kwiatkowski David J, Iafrate A John, Varella-Garcia Marileila, Franklin Wilbur A, Camidge D Ross, Sequist Lecia V, Haura Eric B, Ladanyi Mark, Kurland Brenda F, Kugler Kelly, Minna John D, Bunn Paul A, Kris Mark |
|
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Chinese journal of cancer 2014 Jul 33 (7): 346-50. Su Jian, Zhang Xu-Chao, An She-Juan, Zhong Wen-Zhao, Huang Ying, Chen Shi-Liang, Yan Hong-Hong, Chen Zhi-Hong, Guo Wei-Bang, Huang Xiao-Sui, Wu Yi-Lo |
|
Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.
Oncology letters 2014 Jul 8 (1): 47-54. Rutkowski Piotr, Gos Aleksandra, Jurkowska Monika, Switaj Tomasz, Dziewirski Wirginiusz, Zdzienicki Marcin, Ptaszy?ski Konrad, Michej Wanda, Tysarowski Andrzej, Siedlecki Janusz |
|
Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.
Clinical chemistry 2014 Jul 60 (7): 1004-11. Liu Xiaoying, Mody Kabir, de Abreu Francine B, Pipas J Marc, Peterson Jason D, Gallagher Torrey L, Suriawinata Arief A, Ripple Gregory H, Hourdequin Kathryn C, Smith Kerrington D, Barth Richard J, Colacchio Thomas A, Tsapakos Michael J, Zaki Bassem I, Gardner Timothy B, Gordon Stuart R, Amos Christopher I, Wells Wendy A, Tsongalis Gregory |
|
Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
Haematologica 2013 Jun 98 (6): 937-44. Driessen Emma M C, van Roon Eddy H J, Spijkers-Hagelstein Jill A P, Schneider Pauline, de Lorenzo Paola, Valsecchi Maria Grazia, Pieters Rob, Stam Ronald |
|
NRAS mutation status is an independent prognostic factor in metastatic melanoma.
Cancer 2012 Aug 118 (16): 4014-23. Jakob John A, Bassett Roland L, Ng Chaan S, Curry Jonathan L, Joseph Richard W, Alvarado Gladys C, Rohlfs Michelle L, Richard Jessie, Gershenwald Jeffrey E, Kim Kevin B, Lazar Alexander J, Hwu Patrick, Davies Michael |
|
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Molecular cancer therapeutics 2012 Feb 11 (2): 485-91. Chaft Jamie E, Arcila Maria E, Paik Paul K, Lau Christopher, Riely Gregory J, Pietanza M Catherine, Zakowski Maureen F, Rusch Valerie, Sima Camelia S, Ladanyi Marc, Kris Mark |
|
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
The New England journal of medicine 2008 May 358 (18): 1909-18. Schlenk Richard F, Döhner Konstanze, Krauter Jürgen, Fröhling Stefan, Corbacioglu Andrea, Bullinger Lars, Habdank Marianne, Späth Daniela, Morgan Michael, Benner Axel, Schlegelberger Brigitte, Heil Gerhard, Ganser Arnold, Döhner Hartmut, |
|
BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
The Journal of investigative dermatology 2005 Aug 125 (2): 312-7. Akslen Lars A, Angelini Sabrina, Straume Oddbjørn, Bachmann Ingeborg M, Molven Anders, Hemminki Kari, Kumar Raj |
- Page last reviewed:Jul 30, 2019
- Page last updated:Sep 18, 2019
- Content source: